Skip to main content
Figure 2 | BMC Pharmacology and Toxicology

Figure 2

From: The soluble guanylyl cyclase activator BAY 60-2770 ameliorates detrusor dysfunction in obese mice

Figure 2

Effect of chronic treatment with BAY 60-2770 (1 mg/kg, 2 weeks) on cGMP levels (A) and protein expression of α1 (B) and β1 (C) subunits of sGC in bladders from lean + vehicle, lean + BAY 60-2770, obese + vehicle and obese + BAY 60-2770 groups. Data are presented as mean ± SEM. p <0.05 in comparison with lean + vehicle group; †p <0.05 in comparison to obese + vehicle group.

Back to article page